Loading
A European trial testing whether a gentler substitute for high-dose interleukin-2, the drug given after tumour-infiltrating lymphocyte cell therapy, can cut serious side effects while keeping the treatment working, in melanoma, lung and cervical cancer.
PragmaTIL is a Horizon Europe Cancer Mission project (CORDIS 101104684, topic HORIZON-MISS-2022-CANCER-01-03, "Pragmatic clinical trials to optimise treatments for patients with refractory cancers"), coordinated by the Vall d'Hebron Institute of Oncology in Barcelona, running from 1 April 2023 to 31 March 2028 with an EU contribution of about EUR 6.0 million. Tumour-infiltrating lymphocyte adoptive cell therapy normally requires high-dose interleukin-2 to expand and activate the infused cells, and its toxicity is a barrier to use. The project's objectives are to find whether an IL-2 analogue reduces the frequency of grade 3 or higher non-haematological study-related toxicity, to compare quality of life in hospital and over time, and to carry out a health technology assessment and a social return on investment analysis.
ClinicalTrials.gov lists it as NCT06630611, a phase 2 study sponsored by Vall d'Hebron Institute of Oncology in melanoma, non-small-cell lung cancer and cervical cancer, recruiting, with an actual start on 15 January 2025 and a planned enrolment of 40, comparing an IL-2 analogue with high-dose IL-2 after non-myeloablative lymphodepletion and TIL infusion.
Shares TIL therapy, Cervical cancer, Non-small-cell lung cancer.
Shares EU Mission on Cancer (Horizon Europe), Toxicity and quality of life are undervalued.
Shares TIL therapy, Non-small-cell lung cancer.
Shares TIL therapy, Manufacturing cost and time for living and radioactive medicines.
Shares TIL therapy, Manufacturing cost and time for living and radioactive medicines, Melanoma.
Shares TIL therapy, Melanoma.
Shares TIL therapy, Manufacturing cost and time for living and radioactive medicines, Melanoma.
Shares TIL therapy, Manufacturing cost and time for living and radioactive medicines.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/